What is NDC 55150-394?

55150-394 is the product NDC for Fulvestrant, Fulvestrant 50 mg/mL injection, listed with the FDA by Eugia US LLC. It has 1 package NDC, shown above in 10- and 11-digit form.

Eugia US LLC, NDC labeler code 55150. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Fulvestrant?

20 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Fulvestrant NDC 55150-394 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)55150-394Labeler and product segments. Claims need a package NDC.

Product NDC at billing width55150-0394Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
55150-394-02	5515003940255150039402	2 SYRINGE in 1 CARTON (55150-394-02) / 5 mL in 1 SYRINGEMarketed from Jun 30, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Fulvestrant
Generic name (nonproprietary): fulvestrant
Active ingredients: Fulvestrant — 50 mg/mL
Dosage form: Injection
Route: Intravenous
Labeler: Eugia US LLCNDC labeler code 55150
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 215169
Marketing start: Jun 30, 2023
Listing expires: Dec 31, 2026
Other FDA classes: Estrogen Receptor Antagonists (Mechanism)Selective Estrogen Receptor Modulators (Mechanism)
Identifiers: Product ID 55150-394_01fb9018-5093-40e6-bfea-83dee3a5ffc0SPL ID 01fb9018-5093-40e6-bfea-83dee3a5ffc0SPL set ID 80b6dfe6-449d-4e2f-af90-bfbf9b04163bRxCUI 727762UNII 22X328QOC4UPC 0355150394012, 0355150394029
Pharmacologic class: Estrogen Receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N455150039402 followed by a unit qualifier and the quantity

Package 55150-0394-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 3, 2025.

Indications (excerpt from the label)

Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metasta…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 55150-394

What is NDC 55150-394?: 55150-394 is the product NDC for Fulvestrant, Fulvestrant 50 mg/mL injection, listed with the FDA by Eugia US LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Fulvestrant.
What is the active ingredient?: Fulvestrant.
Who is the labeler?: Eugia US LLC, NDC labeler code 55150. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Fulvestrant?: 20 other product NDCs are listed under this name. See all Fulvestrant NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Fulvestrant NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
fulvestrant	Fulvestrant 50 mg/mL	Injection, SolutionIntramuscular	Sagent Pharmaceuticals	25021-471	25021-0471-66
Fulvestrant	Fulvestrant 50 mg/mL	InjectionIntramuscular	BluePoint Laboratories.	68001-626	68001-0626-85
Fulvestrant	Fulvestrant 50 mg/mL	Injection, SolutionIntramuscular	Avenacy, Inc.	83634-203	83634-0203-74
Fulvestrant	Fulvestrant 50 mg/mL	Injection, SolutionIntramuscular	Dr.Reddy's Laboratories Inc	43598-262	43598-0262-23
Fulvestrant	Fulvestrant 50 mg/mL	InjectionIntramuscular	Sandoz Inc	0781-3532	00781-3532-12
Fulvestrant	Fulvestrant 50 mg/mL	InjectionIntramuscular	Sandoz Inc	0781-9055	00781-9055-12
Fulvestrant	Fulvestrant 50 mg/mL	InjectionIntramuscular	Alembic Pharmaceuticals Inc.	62332-650	62332-0650-10
Fulvestrant	Fulvestrant 50 mg/mL	InjectionIntramuscular	Hikma Pharmaceuticals USA Inc.	0143-9022	00143-9022-02
Fulvestrant	Fulvestrant 50 mg/mL	Injection, SolutionIntramuscular	Zydus Pharmaceuticals USA Inc.	70710-1688	70710-1688-08
Fulvestrant	Fulvestrant 50 mg/mL	Injection, SolutionIntramuscular	Zydus Lifesciences Limited	70771-1626	70771-1626-08

All 21 Fulvestrant NDCs